RVMD
Revolution Medicines, Inc. NASDAQ$147.90
Pre-mkt
$147.79
-0.07%
Mkt Cap $31.4B
52w Low $34.00
93.6% of range
52w High $155.70
50d MA $111.61
200d MA $76.33
P/E (TTM)
-23.4x
EV/EBITDA
-13.7x
P/B
16.3x
Debt/Equity
0.1x
ROE
-69.3%
P/FCF
-16.6x
RSI (14)
—
ATR (14)
—
Beta
1.01
50d MA
$111.61
200d MA
$76.33
Avg Volume
2.8M
About
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a pr…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | 1M% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 25, 2026 | AMC | -1.58 | -1.86 | -17.7% | 103.24 | -7.5% | -1.1% | -1.2% | -1.6% | -2.7% | -2.0% | -10.4% | — |
| Nov 5, 2025 | AMC | -1.42 | -1.61 | -13.4% | 59.34 | +0.7% | +3.4% | +2.8% | +5.7% | +8.0% | +10.9% | +34.2% | — |
| Aug 6, 2025 | AMC | -0.94 | -1.31 | -39.4% | 36.67 | -6.8% | -4.7% | -4.6% | -5.4% | -3.8% | -1.6% | +10.4% | — |
| May 7, 2025 | AMC | -1.12 | -1.13 | -0.9% | 37.66 | +8.3% | +11.3% | +7.3% | +11.2% | +6.1% | +4.8% | +9.1% | — |
| Feb 26, 2025 | AMC | -1.01 | -1.12 | -10.9% | 40.50 | -1.5% | -3.5% | +0.6% | -5.3% | -6.3% | -2.2% | -7.8% | — |
| Nov 6, 2024 | AMC | -0.89 | -0.94 | -5.2% | 59.42 | -2.4% | -0.5% | +1.7% | +2.0% | -0.2% | -2.2% | -19.1% | — |
| Aug 7, 2024 | AMC | -0.77 | -0.81 | -5.2% | 42.27 | -5.1% | -0.7% | +1.5% | +1.7% | +1.7% | +0.7% | -1.0% | — |
| May 8, 2024 | AMC | -0.75 | -0.70 | +6.2% | 38.31 | +2.5% | -2.2% | -2.8% | -3.0% | -2.4% | +2.8% | +5.3% | — |
| Feb 26, 2024 | AMC | -0.86 | -1.14 | -32.6% | 30.38 | +4.1% | +0.8% | -1.4% | -3.0% | -1.9% | -2.9% | +4.4% | — |
| Nov 6, 2023 | AMC | -1.01 | -0.99 | +2.0% | 21.54 | -0.9% | -0.2% | -1.7% | -7.1% | -8.5% | -8.8% | +11.3% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 22 | Leerink Partners | Maintains | Outperform → Outperform | — | $148.90 | $149.67 | +0.5% | -5.0% | -9.7% | -9.1% | -11.6% | -2.7% |
| Apr 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $148.90 | $149.67 | +0.5% | -5.0% | -9.7% | -9.1% | -11.6% | -2.7% |
| Apr 20 | Stifel | Maintains | Buy → Buy | — | $148.63 | $151.85 | +2.2% | -1.6% | +0.2% | -4.8% | -9.5% | -9.0% |
| Apr 20 | Needham | Maintains | Buy → Buy | — | $148.63 | $151.85 | +2.2% | -1.6% | +0.2% | -4.8% | -9.5% | -9.0% |
| Apr 14 | Wells Fargo | Maintains | Overweight → Overweight | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
| Apr 14 | Wedbush | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
| Apr 14 | Evercore ISI | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
| Apr 14 | Guggenheim | Maintains | Buy → Buy | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
| Apr 14 | RBC Capital | Maintains | Outperform → Outperform | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
| Apr 14 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $136.30 | $136.50 | +0.1% | +7.9% | +11.9% | +9.5% | +9.0% | +7.3% |
Recent Filings
8-K · 1.01
! Medium
Revolution Medicines, Inc. -- 8-K 1.01: Underwriting / Securities
Revolution Medicines issued convertible notes on April 17, 2026, with U.S. Bank Trust Company as trustee, providing the company with capital funding while offering investors conversion rights into equity.
Apr 17
8-K
Unknown — 8-K Filing
RVMD completed an equity underwriting with standard indemnification provisions, indicating a secondary offering that will dilute existing shareholders while providing capital for operations or strategic initiatives.
Apr 16
8-K
Unknown — 8-K Filing
Revmed's daraxonrasib advancement toward regulatory submission offers potential upside if efficacy data proves compelling, but substantial development risks mean stock performance heavily depends on upcoming clinical results.
Apr 13
8-K
Unknown — 8-K Filing
Revolution Medicines secured up to $1 billion in non-dilutive financing tied to daraxonrasib's FDA approval milestones, reducing capital needs while Royalty Pharma gains royalty upside if the drug achieves blockbuster sales.
Apr 13
8-K
Revolution Medicines, Inc. -- 8-K Filing
Revolution Medicines reported 2025 full-year financial results and corporate updates, with the late-stage oncology company continuing development of targeted RAS-cancer therapies.
Feb 25
Data updated apr 26, 2026 11:43pm
· Source: massive.com